Berberine inhibits glucose oxidation and insulin secretion in rat islets

Bai, Mengyao; Liu, Yun; Zhou, Feiye; Zhang, Yuqing; Zhu, Qin; Zhang, Linlin; Zhang, Qi; Wang, Shushu; Zhu, Ke-Cheng; Wang, Xiao; Zhou, Libin

doi:10.1507/endocrj.ej17-0543

Cited by 18 publications

(16 citation statements)

References 30 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). This effect was found in pancreatic islets of rat, mouse and also human [3, 13, 40, 73]. In spite of some species differences related to β cell biology [41, 63, 69], the results regarding AMPK indicate that the influence of glucose is similar in rodent and human islets.…”

Section: The Link Between Ampk and Insulin Secretionmentioning

confidence: 97%

“…Insulin secretion is a dynamic process and changes rapidly in response to various regulatory agents. In this context, the phosphorylation level of AMPKα (Thr172) was shown to be reduced already after short-term (30–60 min) exposure of pancreatic islets to glucose [3, 32, 73]. However, in the case of more prolonged (16–20 h) incubations of islets with increased concentrations of glucose, pAMPK is also reduced [13, 32].…”

Section: The Link Between Ampk and Insulin Secretionmentioning

confidence: 99%

See 1 more Smart Citation

The relevance of AMP-activated protein kinase in insulin-secreting β cells: a potential target for improving β cell function?

Szkudelski

Szkudelska

2019

J Physiol Biochem

View full text Add to dashboard Cite

AMP-activated protein kinase (AMPK) is present in different kinds of metabolically active cells. AMPK is an important intracellular energy sensor and plays a relevant role in whole-body energy homeostasis. AMPK is activated, among others, in response to glucose deprivation, caloric restriction and increased physical activity. Upon activation, AMPK affects metabolic pathways leading to increased formation of ATP and simultaneously reducing ATP-consuming processes. AMPK is also expressed in pancreatic β cells and is largely regulated by glucose, which is the main physiological stimulator of insulin secretion. Results of in vitro studies clearly show that glucose-induced insulin release is associated with a concomitant inhibition of AMPK in β cells. However, pharmacological activation of AMPK significantly potentiates the insulin-secretory response of β cells to glucose and to some other stimuli. This effect is primarily due to increased intracellular calcium concentrations. AMPK is also involved in the regulation of gene expression and may protect β cells against glucolipotoxic conditions. It was shown that in pancreatic islets of humans with type 2 diabetes, AMPK is downregulated. Moreover, studies with animal models demonstrated impaired link between glucose and AMPK activity in pancreatic islet cells. These data suggest that AMPK may be a target for compounds improving the functionality of β cells. However, more studies are required to better elucidate the relevance of AMPK in the (patho)physiology of the insulin-secreting cells.

show abstract

Section: The Link Between Ampk and Insulin Secretionmentioning

confidence: 97%

Section: The Link Between Ampk and Insulin Secretionmentioning

confidence: 99%

The relevance of AMP-activated protein kinase in insulin-secreting β cells: a potential target for improving β cell function?

Szkudelski

Szkudelska

2019

J Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…7C). It was previously demonstrated that insulin secretion was reduced from rat islets pretreated with media containing BBR (Bai et al, 2018). Reductions in insulin secretion under low glucose conditions were detected when palmitate was added to the media (Zhou et al, 2008).…”

Section: Dietary Bbr Supplementation Preserved Pancreatic β-Cell Funcmentioning

confidence: 98%

Berberine Alleviates Adiposity and Cardiac Dysfunction in Offspring Exposed to Gestational Diabetes Mellitus

Cole

Zhang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

The most robust risk factor for type 2 diabetes in childhood is prior exposure to diabetes during gestation. Currently, there are few evidence-based strategies to attenuate the of risk of metabolic syndrome in offspring exposed to gestational diabetes mellitus (GDM). Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese herbs and exhibits glucose lowering properties. It has been used safely for centuries in humans. Our objective was to determine whether BBR treatment improves health outcomes in the mouse offspring of GDM dams. Dams were fed either a lean low-fat diet (Lean, LF,10% kcal fat) or a GDM-inducing high-fat/high sucrose diet (GDM, HF, 45% kcal fat) prior to breeding and throughout pregnancy. The resulting Lean and GDM-exposed offspring were randomly assigned a LF, HF or HF diet containing BBR (160 mg/kg/d) for 12 weeks. We determined that BBR treatment significantly reduced body weight (∼20%), % body fat (∼40%) and gonadal fat pad mass (∼60%) compared to HF-fed GDM offspring. Furthermore, BBR treatment of HF-fed GDM offspring normalized insulin levels in the plasma and isolated pancreatic islets. Differences in food consumption did not contribute to altered body composition in BBR treated mice, as levels remained similar between experimental groups. Alternatively, BBR-treatment was associated with increased whole-body oxygen consumption (VO2), activity and heat production. Additionally, we determined that HF-fed GDM offspring developed a cardiomyopathy, characterized by increased isovolumetric contraction (∼150%, IVCT), relaxation time (∼70%, IVRT), elevated cardiac triglyceride (∼120%) and reduced mitochondrial function (30%, spare capacity) compared to LF fed Lean controls. BBR treatment normalized heart function, reduced triglyceride levels and maintained mitochondrial function. Our data supports BBR as a potential pharmacotherapeutic approach to improve health outcomes in individuals exposed to GDM.Key Points SummaryGestational diabetes mellitus is a common metabolic complication of pregnancy which is increasing worldwide due to the prevalence of obesity.It is known that individuals exposed to gestational diabetes have elevated risk of developing metabolic syndrome however there are few evidence-based strategies which provide protection.Berberine is a natural compound found in Chinese herbs which has been safely used for centuries to treat type 2 diabetes mellitus.We determined that berberine treatment of offspring exposed to gestational diabetes attenuated weight gain, reduced insulin levels and normalized both heart and pancreatic function.Our data supports berberine as a potential pharmacotherapeutic approach to improve health outcomes in individuals exposed to gestational diabetes.

show abstract

“…Research on the mechanism of action in this area is relatively scarce. One possible mechanism is BBR inhibited GSIS via the KATP-dependent triggering pathway [ 56 ].…”

Section: Studies On the Bbr Mechanismmentioning

confidence: 99%

Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment

Han

Xiang

Shi

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Traditional Chinese medicine (TCM) has good clinical application prospects in diabetes treatment. In addition, TCM is less toxic and/or has fewer side effects and provides various therapeutic effects. Berberine (BBR) is isolated as the main component in many TCM kinds (e.g., Rhizoma Coptidis and Berberidis Cortex). Furthermore, BBR can reduce blood sugar and blood fat, alleviate inflammation, and improve the state of patients. Based on the recent study results of BBR in diabetes treatment, the BBR pharmacokinetics and mechanism on diabetes are mainly studied, and the specific molecular mechanism of related experimental BBR is systematically summarized and analyzed. Clinical studies have proved that BBR has a good therapeutic effect on diabetes, suggesting that BBR may be a promising drug candidate for diabetes. More detailed BBR mechanisms and pathways of BBR need to be studied further in depth, which will help understand the BBR pharmacology in diabetes treatment.

show abstract

Berberine inhibits glucose oxidation and insulin secretion in rat islets

Cited by 18 publications

References 30 publications

The relevance of AMP-activated protein kinase in insulin-secreting β cells: a potential target for improving β cell function?

The relevance of AMP-activated protein kinase in insulin-secreting β cells: a potential target for improving β cell function?

Berberine Alleviates Adiposity and Cardiac Dysfunction in Offspring Exposed to Gestational Diabetes Mellitus

Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment

Contact Info

Product

Resources

About